RemeGen (HKG:9995) said it was lifting the price cap on the repurchase of its shares from the open market, according to a Hong Kong bourse filing Thursday.
Shares of the biopharmaceutical research company gained nearly 3% in morning trade Friday.
The firm will now pay up to 116 yuan per share as opposed to the previous cap of 95 million yuan apiece previously.
The company's board approved a share repurchase program in December to buy back between 20 million yuan and 40 million yuan worth of stocks.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments